BiomX buys RondinX in Israeli microbiome merger
BiomX develops therapies that target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (IBD) and cancer.
Microbiome therapeutics co BiomX raises $24m
BiomX CEO Jonathan Solomon said, “RondinX developed a superior computational platform that provides an accurate picture of the residing bacterial strains present in the microbiome samples of large cohorts of patients as well as their growth dynamics. This merger of capabilities brings BiomX’s target discovery capabilities to the forefront of microbiome analysis, and at the same time supports the development of our lead inflammatory bowel disease and cancer products.”
RondinX’s technology is based on pioneering at the Weizmann Institute of Science and exclusively licensed to RondinX from its commercial arm YEDA Research and Development Company Ltd. In the research, Profs. Eran Segal and Eran Elinav demonstrated the link between certain members of the microbiome community and specific disease states by incorporating prediction of bacterial growth dynamics into microbiome analysis. The findings were published in Science in 2015.
BiomX is a microbiome drug discovery company developing customized phage therapies that target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (IBD) and cancer. We discover and validate proprietary bacterial targets and customize our natural and engineered phage compositions against these targets.
Published by Globes [online], Israel business news – www.globes-online.com – on December 26, 2017
© Copyright of Globes Publisher Itonut (1983) Ltd. 2017